Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 2CNS 2Sarcoma 1NET 1Gynecologic 1Genitourinary 1Endocrine 1

Conditions

Neuroendocrine Tumors 69Pheochromocytoma 8Gastro-enteropancreatic neuroendocrine tumor 8Carcinoma, Neuroendocrine 8Paraganglioma 7Carcinoid Tumor 7Adenoma, Islet Cell 7Sarcoma 6Thyroid Neoplasms 5Pancreatic Neoplasms 5Neoplasms 5Melanoma 5Breast Neoplasms 5Prostatic Neoplasms 4Ovarian Neoplasms 4Neuroblastoma 4Neoplasm Metastasis 4Mesothelioma 4Carcinoma, Merkel Cell 4Carcinoma 4Stomach Neoplasms 3Neuroectodermal Tumors, Primitive 3Meningioma 3Liver Neoplasms 3Gallbladder Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 3Cholangiocarcinoma 3Central Nervous System Neoplasms 3Carcinoma, Non-Small-Cell Lung 3

Interventions

Tirapazamine 1Ethiodized Oil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hypoxia × NET × 90 days × Clear all
NCT02174549 2026-04-20

Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Teclison Ltd.

Phase 1/2 Recruiting
25 enrolled
EndocrineGastrointestinalNET

Hypoxia, Carcinoma, Hepatocellular, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡